Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Central modulation of pain
Michael H. Ossipov, … , Gregory O. Dussor, Frank Porreca
Michael H. Ossipov, … , Gregory O. Dussor, Frank Porreca
Published November 1, 2010
Citation Information: J Clin Invest. 2010;120(11):3779-3787. https://doi.org/10.1172/JCI43766.
View: Text | PDF
Review Series

Central modulation of pain

  • Text
  • PDF
Abstract

It has long been appreciated that the experience of pain is highly variable between individuals. Pain results from activation of sensory receptors specialized to detect actual or impending tissue damage (i.e., nociceptors). However, a direct correlation between activation of nociceptors and the sensory experience of pain is not always apparent. Even in cases in which the severity of injury appears similar, individual pain experiences may vary dramatically. Emotional state, degree of anxiety, attention and distraction, past experiences, memories, and many other factors can either enhance or diminish the pain experience. Here, we review evidence for “top-down” modulatory circuits that profoundly change the sensory experience of pain.

Authors

Michael H. Ossipov, Gregory O. Dussor, Frank Porreca

×

Figure 2

Schematic representation of bulbospinal pain inhibition and potential targets of analgesic activity.

Options: View larger image (or click on image) Download as PowerPoint
Schematic representation of bulbospinal pain inhibition and potential ta...
(A) Descending pain inhibition from the PAG can be initiated by electrical stimulation or direct microinjection of opioids. Recent evidence also indicates a role for COX inhibitors in the PAG as well. Opioids and cannabinoids inhibit pain by enhancing the baseline firing rate of off-cells and eliminating the off-cell pause in response to nociceptive stimuli. Inhibition of on-cell activity may abolish enhanced pain states. The on-cells and off-cells might correlate with pain facilitatory (+) and inhibitory (–) neurons in the RVM, respectively. At the level of the spinal cord, opioids can inhibit transmitter release from primary afferent terminals as well as activity of pain transmission neurons. Norepinephrine (NE) release from spinopetal noradrenergic fibers from medullary sites also inhibits pain transmission. Tricyclic antidepressants (TCAs) and other norepinephrine reuptake inhibitors enhance the antinociceptive effect of opioids by increasing the availability of spinal norepinephrine (box). Areas labeled “i–iii” in the small diagram correspond with labeled details of the larger diagram. α2A, α2-adrenergic receptor; DRG, dorsal root ganglion; SNRI, serotonin/norepinephrine reuptake inhibitor; SP, substance P. (B) Mice deficient in dopamine β-hydroxylase that do not produce norepinephrine show a diminished antinociceptive effect of morphine compared with control animals, suggesting that the presence of norepinephrine, presumably released in the spinal cord, is required for the full expression of morphine antinociception. The dashed line represents the 50% effect, and the corresponding dose is the ED50 (that is the dose producing a 50% effect). % MPE, percentage maximal possible effect. ***P < 0.001 compared with the control group. Error bars represent SEM. Copyright National Academy of Sciences, USA (151).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts